Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Maxeon stock plummets 25% on Q2 revenue miss and soft guidance; Goldman remains Buy-rated

Published 10/08/2023, 23:02
Updated 11/08/2023, 11:46
© Reuters.

Maxeon (NASDAQ:MAXN) shares plunged about 25% in premarket Friday following the company's reported Q2 results.

Revenue of $348.4 million came in worse than the consensus estimate of $378.23M. EPS was ($0.03), compared to the consensus estimate of ($0.07).

"The demand environment in the global distributed generation (DG) market weakened significantly in late-Q2 due to the combined effect of higher interest rates, the impact of policy disruption in California, and significant channel inventory industry-wide. Our DG sales team was able to deliver on-plan ASP and gross profit but came in short of target on volume and revenue,” said CEO Bill Mulligan.

For Q3/23, the company expects revenue in the range of $280M-$320M, missing the consensus estimate of $395.3M (NYSE:MMM). Adjusted EBITDA is seen at $2M-$12M.

For the full year, the company anticipates revenue in the range of $1.25B-$1.35B, worse than the consensus of $1.51B. Adjusted EBITDA is seen at $80M-$100M.

Goldman Sachs analysts remain Buy-rated on the stock, "but acknowledge near-term DG demand and the ongoing dispute with SPWR would be key focus areas into 2H23."

The analysts cut the price target by $6 to $37 per share.

(Additional reporting by Senad Karaahmetovic)

 
 
 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.